United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Phase III evidence elevates BREZTRI in the competitive asthma landscape Phase III data position AstraZeneca Plc’s BREZTRI for asthma growth. Discover the strategic, financial, and competitive implications. bySoujanya RaviFebruary 15, 2026